Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2008

Originalarbeiten

  • Schulz H, Rehwald U, Morschhauser F, Elter T , Driessen C, Rüdiger T, Borchamnn P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte predominant Hodgkin Lymphoma: Long-term results of a phase 2 trial of the German Hodgkin Lymphoma Study Group (GHSG). Blood 111:109-111 (2008)
  • Macann A, Bredenfeld H, Müller RP, Diehl V, Engert A, Eich HT. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin’s lymphoma treated with the BAGCOPP regimen: A report by the German Hodgkin’s Lymphoma Study Group. Int J Radiat Oncol Biol Phys 70(1):161-165 (2008)
  • Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, Engert A. Fertility in male patients with advanced Hodgkin Lymphoma treated with BEACOPP: A report from the German Hodgkin Study Group (GHSG). Blood 111:71-76 (2008)
  • Nogova L, Reineke T, Brillant C, Rüdiger T, Bredenfeld H, Josting A, Müller R-P, Müller-Hermelink H-K, Diehl V, Engert A for the GHSG. Lymphocyte Predominant and Classical Hodgkin Lymphoma: A comprehensive analysis from the German Hodgkin Study Group (GHSG). J Clin Oncol, Jan 20: 434-439 (2008)
  • Schnell R, Dietlein, M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 ibritumomab tiuxetan induced omplete remission in a patient with classical lymphocyte-rich Hodgkin Lymphoma. Onkologie Feb 31(1-2):49-51 (2008)
  • Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, Oliff IA, Rummel MJ, Österborg A. Phase I study of a novel pro-apoptotic drug R-Etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs 26(2):139-49  (2008)
  • Rothe A, Nathanielsz A, Oberhäuser F, Pogge von Strandmann E, Engert A, Hudson P, Power B. Ribosome display and selection of human anti-CD22 scFvs derived from an acute lymphocytic leukemia patient. Biol Chem April; 389:433-439 (2008)
  • Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg MF, Petersen J, Losic N, Radford J. First clinical use of Ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase I/II trial. Blood, June 15; 111(12):5486-5495 (2008)
  • Klimm B, Engert A. Combined modality treatment with two cycles of chemotherapy prior to radiotherapy is superior to radiotherapy alone in early-stage favorable Hodgkin Lymphoma. Case Study. For the German Hodgkin Study Group (GHSG). Am J Hem/Onc July 7(7):291-294 (2008)
  • Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, Fuchs M, Diehl V, Engert A. Assessment of male fertility in patients with Hodgkin Lymphoma treated in the German Hodgkin Study Group (GHSG) - clinical trials. Ann Oncol, Oct 19(10):1795-801 (2008)
  • Klimm B, Engert A. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. Nat Clin Pract Oncol, June 5(6):316-23 (2008)
  • Quellmann S, Schwarzer G, Hübel K, Engert A, Bohlius J. Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. Leukemia, Sept 22(9):1801-3 (2008) IF:8.6
  • Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Mueller RP, Fuchs M, Borchmann P, Schicha H, Diehl V, Engert A. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin Lymphoma. Blood, Nov 112:3989-3994 (2008)
  • Rautert R, Schinkoethe T, Franklin J, Weihrauch M,  Böll B, Pogge E, Bredenfeld H, Engert A, Diehl V, Re D. Elevated pretreatment Interleukin-10 serum level is an IPS-independent risk factor for early treatment failure in advanced stage Hodgkin Lymphoma. Leukemia & Lymphoma, Nov 49(11):2091-2098 (2008)
  • Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate Natural Killer function. PloS ONE 3(10):e3377 (2008)
  • Elter T, Vehreschild J, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 88:121-132 (2008)
  • Bohlius J, Engert A, Schwarzer G. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. JAMA 300(24):2854-2855 (2008)
  • Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A. Pharmacokinetics of Alemtuzumab in combination with Fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica,  Nov 10 (2008) [Epub ahead of print]

Übersichtsarbeiten

  • Engert A, Dreyling M. ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol May;19 Suppl 2:ii65-6 (2008)
  • Hansen HP, Engert A. Treatment of CD30-positive diseases, such as Hodgkin’s lymphoma, by administration of a combination of sheddase inhibitor and anti-CD30 immunotherapeutic agents. Expert Opin.Ther.Patents 18(6):671-676 (2008)
  • Engert A. Treatment of lymphocyte-predominant Hodgkin lymphoma. Ann Oncol 19(Suppl 4):iv45-iv46 (2008)
  • Herbst C, Monsef I, Skoetz N, Engert A. Eighth Biannual Report of the Cochrane Haematological Malignancies Group – Focus on Chronic and Acute Lymphatic Leukemia. J Natl Cancer Inst Aug 6;100(15):E1 (2008)
  • Hertl M, Zillikens D, Borradori L, Breitbach M, Bruckner-Tuderman L, Burckhardt H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S. Empfehlungen für den Einsatz von Rituximab (anti-CD20) bei bulösen Autoimmundermatosen – Recommendations for the use of rituximab in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges, May 6(5):366-73 (2008)
  • Fuchs M, Eichenauer D, Nogová L, Diehl V, Engert A. Nodular Lymphocyte Predominant Hodgkin Lymphoma. Curr Hem Mal Rep July 3(3):126-131 (2008) 
  • Eichenauer, D, Fuchs M, Borchmann P, Engert A for the German Hodgkin Study Group (GHSG). Hodgkin Lymphoma: Current treatment strategies and novel approaches. Expert Review of Hematology. Expert Rev Hematol 1(1):63-73 (2008)
  • Kobe C, Dietlein M, Mauz-Körholz C, Engert A, Borchmann P, Sabri O, Schober O, Schicha H, Kluge R. FDG-PET in Hodgkin Lymphoma. Nuklearmedizin 47(6):235-238 (2008)
  • Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 Ibritumomab Tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin’s Lymphoma. Onkologie 31:49-51 (2008)